NUTROPIN AQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NUTROPIN AQ (NUTROPIN AQ).
Recombinant human growth hormone (somatropin) that binds to growth hormone receptor, activating JAK2/STAT5 signaling pathway, leading to increased IGF-1 production and linear growth.
| Metabolism | Metabolized in the liver and kidney via proteolysis; no specific cytochrome P450 involvement. |
| Excretion | Renal: >99% of administered dose excreted via kidneys as intact growth hormone and metabolites. Biliary/fecal: negligible (<1%). |
| Half-life | Terminal half-life: 2.5-3.0 hours for subcutaneous administration. Clinical context: Supports once-daily dosing; levels return to baseline by 12-16 hours post-dose. |
| Protein binding | Approximately 40-50% bound to growth hormone-binding protein (GHBP). |
| Volume of Distribution | 0.5-0.7 L/kg for central volume; total Vd small (approx. 50-100 mL/kg), consistent with limited extravascular distribution. |
| Bioavailability | Subcutaneous: approximately 80% (range 70-90%) relative to intravenous administration. |
| Onset of Action | Subcutaneous: 2-4 hours for increase in insulin-like growth factor-1 (IGF-1) levels; metabolic effects (e.g., lipolysis) begin within hours. |
| Duration of Action | Subcutaneous: 18-24 hours based on sustained IGF-1 elevation; clinical growth effects require chronic dosing (months to years). |
0.006 mg/kg subcutaneously once daily.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment. |
| Liver impairment | No specific Child-Pugh based dose adjustment recommended. |
| Pediatric use | 0.3 mg/kg per week divided into daily subcutaneous doses (e.g., 0.043 mg/kg/day). |
| Geriatric use | Lower starting dose recommended due to increased sensitivity; individualize based on response and adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NUTROPIN AQ (NUTROPIN AQ).
| Breastfeeding | Excretion into human milk unknown. Caution advised due to potential for adverse effects in nursing infant. M/P ratio not established. |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in pregnant women. Somatropin is not teratogenic in animal studies at doses up to 35 times human dose. Fetal growth effects unknown. Avoid use in first trimester unless benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure; contraindicated in PWS with severe obesity, history of upper airway obstruction, sleep apnea, or severe respiratory impairment.
| Serious Effects |
["Acute critical illness (open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure)","Active malignancy (contraindicated for growth promotion in children with cancer, antineoplastic therapy must be completed first)","Diabetic retinopathy (active proliferative or non-proliferative)","Hypersensitivity to somatropin or excipients","Prader-Willi syndrome with severe obesity or severe respiratory impairment (apnea, upper airway obstruction)","Closed epiphyses (for pediatric growth indications)"]
| Precautions | ["Increased risk of neoplasms (especially second neoplasms in childhood cancer survivors)","Increased risk of intracranial hypertension (pseudotumor cerebri)","Slipped capital femoral epiphysis in children","Progression of scoliosis","Pancreatitis (especially in children)","Fluid retention (peripheral edema, arthralgia, carpal tunnel syndrome)","Glucose intolerance/diabetes mellitus","Hypoadrenalism in patients with secondary adrenal insufficiency","Hypothyroidism (may become clinically evident)","Leukemia risk (potential association)","Severe hypersensitivity reactions"] |
Loading safety data…
| Monitor maternal glucose tolerance (somatropin may induce insulin resistance). Fetal growth and well-being via ultrasound. Maternal blood pressure and thyroid function. |
| Fertility Effects | Somatropin may improve fertility in women with growth hormone deficiency by restoring ovulation. No known adverse effects on spermatogenesis in males. |